Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer.

被引：0

作者：

Shen, Bo ^{[1
]}

Wu, Yuan ^{[1
]}

机构：

[1] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Internal Med Oncol, Nanjing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

703

引用

页码：703 / 703

页数：1

共 50 条

[1] Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction
Peng, Zhi
Wei, Jia
Wang, Feng
Ying, Jieer
Deng, Yanhong
Gu, Kangsheng
Cheng, Ying
Yuan, Xianglin
Xiao, Juxiang
Tai, Yanfei
Wang, Linna
Zou, Jianjun
Zhang, Yanqiao
Shen, Lin
CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3069 - 3078
[2] Camrelizumab plus apatinib combined with TACE and cryoablation in the first-line treatment of advanced hepatocellular carcinoma.
Xing, Wenge
Guo, Zhi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Camrelizumab combined with EP/EC chemotherapy followed by camrelizumab plus apatinib for first-line therapy of advanced extrapulmonary neuroendocrine carcinoma: A prospective, single-arm, multicenter clinical study
Dai, Y.
Hong, Q.
ANNALS OF ONCOLOGY, 2023, 34 : S710 - S710
[4] Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.
Shen, Lin
Peng, Zhi
Zhang, Yan-Qiao
Wei, Jia
Wang, Feng
Ying, Jieer
Deng, Yanhong
Gu, Kangsheng
Cheng, Ying
Yuan, Xianglin
Xiao, Juxiang
Wang, Linna
Zou, Jianjun
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.
Ni, Jun
Zhang, Xiaotong
Pan, Ruili
Wang, Hanping
Si, Xiaoyan
Cui, Xiaoxia
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study
Pu, Xingxiang
Lin, Gen
Xiao, Maoliang
Lin, Jie
Wang, Qianzhi
Kong, Yi
Yan, Xuejun
Xu, Fang
Xu, Yan
Li, Jia
Li, Kang
Chen, Bolin
Wen, Xiaoping
Tan, Yali
Cheng, Fengzhuo
Zhu, Kangle
Li, Na
Wu, Lin
ECLINICALMEDICINE, 2024, 67
[7] First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma A case series and review of the literature
Kong, Feng-Wei
Wang, Wei-Min
Liu, Lei
Wu, Wen-Bin
Wang, Xiang
Zhang, Miao
MEDICINE, 2020, 99 (23)
[8] Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.
Zhao, Yanbin
Zhang, Minghui
Liu, Jinglei
Pu, Haihong
Li, Yinghong
Li, Xin
Wang, Yan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report
Wu, Jing
Wang, Zheng
Li, Jing
Peng, Xue-Hui
Tang, Yi-Chen
Huang, Xiao-Bing
He, Yong-Gang
FRONTIERS IN ONCOLOGY, 2022, 12
[10] PD-1 antibody combined with paclitaxel (albumin bound) and gemcitabine as first-line therapy in patients with metastatic pancreatic cancer.
Cui, Jiujie
Yao, Jiayu
Wang, Yu
Liang, Yiyi
Wang, Yongchao
Jiao, Feng
Zhang, Xiao
Han, Ting
Mao, Tiebo
Xia, Qing
Xiao, Xiuying
Yang, Haiyan
Wang, Li-Wei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →